IGF2BP1-Mediated m6A Regulation of Macrophage Metabolism in Pulmonary Fibrosis

Study Background and Research Question

Pulmonary fibrosis (PF) is a progressive, often fatal disease characterized by excessive extracellular matrix (ECM) deposition and fibroblast proliferation, leading to irreversible lung function decline. The pathogenic mechanisms underlying PF are multifactorial, with macrophages playing central roles in both the initiation of inflammation and the promotion of fibrotic remodeling. Of particular interest is the polarization of macrophages: M1-like macrophages are associated with inflammation, while M2-like macrophages are implicated in tissue remodeling and fibrosis. Recent advances have highlighted the importance of metabolic reprogramming—specifically, increased glycolysis—in driving the profibrotic activities of macrophages.

Epigenetic regulation, particularly N6-methyladenosine (m6A) RNA modification, has emerged as a key modulator of mRNA stability and gene expression in diverse biological contexts, including fibrotic disease. However, the precise mechanisms linking m6A readers such as insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) to macrophage metabolism and PF progression have remained unclear. The referenced study (Hu et al., 2025) aimed to dissect how IGF2BP1 influences macrophage function and metabolic phenotypes to drive pulmonary fibrosis.

Key Innovation from the Reference Study

The central innovation of Hu et al. (2025) lies in identifying a novel regulatory axis—IGF2BP1/THBS1/TLR4—that integrates m6A-dependent post-transcriptional control with metabolic and phenotypic reprogramming of macrophages during PF. Specifically, the study demonstrates that IGF2BP1 binds to and stabilizes thrombospondin-1 (THBS1) mRNA in an m6A-dependent manner, thereby enhancing THBS1 expression. This, in turn, activates toll-like receptor 4 (TLR4) signaling, promoting M2 polarization and glycolytic activation of macrophages, both of which are critical for fibrotic progression.

This mechanistic insight bridges the gap between epigenetic regulation (via m6A readers), metabolic reprogramming, and immune-mediated fibrosis, offering a new conceptual framework for understanding—and potentially intervening in—fibrotic lung diseases.

Methods and Experimental Design Insights

The authors used a multi-pronged approach combining in vivo and in vitro systems. Key methodological components included:

• Induction of pulmonary fibrosis in mice using bleomycin (BLM), a well-established model for studying fibrotic processes.
• Genetic knockdown of IGF2BP1 in macrophages to assess its functional role in PF pathology.
• Histological and biochemical evaluation of lung tissue, including Ashcroft scoring, hydroxyproline content (collagen quantification), and immunostaining for fibrotic markers.
• RNA and protein analyses to measure the expression of fibrosis-associated genes (e.g., TGF-β1, α-SMA, Collagen-I/III), M2 macrophage markers (Arg1, CCL18, Ym1, CD163), and inflammatory cytokines (IL-6, IL-1β, TIMP1).
• Mechanistic studies to explore IGF2BP1-THBS1 mRNA interactions (e.g., RNA immunoprecipitation), and the role of m6A methylation in mRNA stability.
• Metabolic assays to quantify glycolytic enzyme expression (HK2, LDHA, PKM2), lactate and glucose flux, and ATP production.
• Overexpression and rescue experiments for THBS1 and TLR4 to delineate their roles downstream of IGF2BP1.

This comprehensive methodological design enabled the authors to causally link IGF2BP1 activity with metabolic and phenotypic changes in macrophages, and to dissect the molecular intermediates involved.

Protocol Parameters

• Bleomycin-induced PF model: Bleomycin administration to mice (typical single dose, intratracheal, as per established protocols) to trigger lung fibrosis.
• Gene knockdown: Use of siRNA or shRNA targeting IGF2BP1 in macrophages, validated by qPCR and immunoblotting, to assess functional consequences.
• Macrophage polarization assays: Flow cytometry for CD68+/CD163+ populations, and qPCR for M2 markers (Arg1, CCL18, Ym1).
• Metabolic readouts: Measurement of glycolytic enzyme expression (HK2, LDHA, PKM2), lactate production, and ATP levels to quantify glycolytic flux.
• m6A modification analysis: RNA immunoprecipitation and m6A-specific pulldown to confirm IGF2BP1-THBS1 mRNA interaction.
• Rescue experiments: THBS1 or TLR4 overexpression to validate their position downstream of IGF2BP1.

Core Findings and Why They Matter

The study demonstrates several interconnected findings:

• IGF2BP1 is upregulated in macrophages during pulmonary fibrosis, and its knockdown attenuates BLM-induced lung pathology, reducing fibroblast accumulation, ECM deposition, and overall fibrotic severity (Hu et al., 2025).
• Depletion of IGF2BP1 downregulates multiple profibrotic and proinflammatory markers in lung tissue and embryonic lung fibroblasts, including TGF-β1, α-SMA, Collagen-I/III, Arg1, CCL18, Ym1, CD163, IL-6, and IL-1β.
• IGF2BP1 directly interacts with and stabilizes THBS1 mRNA in an m6A-dependent manner, supporting a post-transcriptional mechanism for regulating profibrotic signaling.
• THBS1 overexpression rescues the impaired M2 polarization and glycolytic metabolism observed upon IGF2BP1 knockdown, restoring glycolytic enzyme expression, lactate/glucose flux, and ATP production.
• THBS1 physically interacts with TLR4, and TLR4 overexpression reverses the deficits in M2 polarization and glycolytic activation caused by THBS1 knockdown.

These findings establish a previously unrecognized IGF2BP1/THBS1/TLR4 axis as a critical driver of macrophage-mediated fibrogenesis, integrating epigenetic, metabolic, and immune signaling. The results provide a rationale for targeting this axis in efforts to modulate macrophage activation, cytokine release, and inflammatory response modulation in fibrotic lung disease.

Comparison with Existing Internal Articles

This research extends and deepens the mechanistic landscape mapped by several recent reviews and workflow articles. For example, "Unleashing the Full Potential of Macrophage Biology" contextualizes the IGF2BP1/THBS1/TLR4 axis within a broader framework of macrophage modulation and translational research, highlighting the importance of precise manipulation of macrophage survival, proliferation, and differentiation. Similarly, "Recombinant Mouse M-CSF: New Insights into Macrophage Regulation" discusses how recombinant M-CSF is used to model macrophage-driven fibrotic pathways, including metabolic and signaling shifts relevant to the findings of Hu et al. (2025).

While previous articles have addressed how tools such as recombinant cytokines support studies of osteoclast progenitor proliferation and macrophage-mediated tumor cell killing, the current reference study uniquely elucidates the epigenetic-metabolic interface, providing direct molecular targets (IGF2BP1, THBS1, TLR4) for future research and therapeutic intervention.

Limitations and Transferability

Despite its significant contributions, the study has several limitations. Most notably, the findings are based primarily on murine models (bleomycin-induced PF and mouse macrophages), which, while highly informative, may not fully recapitulate human disease complexity or heterogeneity. The reliance on overexpression and knockdown strategies, common in mechanistic studies, also raises questions about physiological relevance and potential compensatory mechanisms in vivo. Furthermore, while the IGF2BP1/THBS1/TLR4 axis is clearly delineated in the context of pulmonary fibrosis, its transferability to other organs or fibrotic diseases awaits further validation.

Another consideration is the potential for off-target effects in genetic manipulation and the need for additional studies to clarify whether THBS1/TLR4 signaling interacts with other macrophage activation pathways or metabolic regulators not captured in the current experimental design. Nonetheless, the study's integration of epigenetic, metabolic, and immunological perspectives provides a robust foundation for future translational research.

Research Support Resources

For researchers aiming to model macrophage-driven fibrosis, study macrophage activation and cytokine release, or explore metabolic reprogramming in vitro, access to reliable macrophage growth factors is essential. Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) without Tag (SKU PM2021) from APExBIO supports robust survival, proliferation, and functional differentiation of mouse macrophages, as described in the product information. This reagent can be integrated into workflows investigating the metabolic and signaling pathways highlighted in Hu et al. (2025) and related internal resources, enabling reproducible and physiologically relevant macrophage culture models for advanced fibrosis research.